IRLA — IRulya Therapeutics Share News
0.000.00%
Last trade - 00:00- $355.93m
- $383.76m
U.S. STOCKS ON THE MOVE-CVRx, Tesla, So-Young International
U.S. STOCKS ON THE MOVE-Knight-Swift, BioNTech, US regional banks
Quince Therapeutics gains on buyout offer from Echo Lake Capital
Brief: Echo Lake Capital Offers To Acquire Quince Therapeutics, Inc
Brief: Quince Therapeutics Provides Pipeline Update And Business Outlook For 2023
Brief: Quince Therapeutics Approved Cost Reduction Program
Brief: Quince Therapeutics - On Dec 13, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Quince Therapeutics Presents Preclinical Data At MHSRS 2022
Brief: Quince Therapeutics Details Strategic Growth Plan With Launch Of New Corporate Name
Brief: Cortexyme Successfully Completes Phase 1 Single And Multiple Ascending Dose Clinical Trial Of COR588
Brief: Cortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022
Brief: Cortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus Infections
U.S. RESEARCH ROUNDUP- Appfolio, Hyatt Hotels, TransDigm Group
Brief: Cortexyme Announces Agreement To Acquire Novosteo
Brief: Cortexyme - Co Is Further Reducing Headcount By 36%, Bringing Total Reduction To 67% From January 2022 Headcount Levels
Brief: Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits Of Atuzaginstat
Cortexyme jumps after positive safety data on bacterial disorder drug
Brief: Cortexyme Reports Results From Phase 1 Clinical Trial Of COR588
Brief: Cortexyme Announces Change In Executive Leadership Team